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Abstract
Greater understanding of cognitive function in children and adolescents with bipolar disorder (BD) 
is of critical importance to improve our ability to design targeted treatments to help with real-
world impairment, including academic performance. We sought to evaluate cognitive performance 
among children with either BD type I, II, or “not otherwise specified” (NOS) participating in 
multi-site Course and Outcome of Bipolar Youth study compared to typically developing controls 
(TDC) without psycho-pathology. In particular, we sought to test the hypothesis that BD-I and 
BD-II youths with full threshold episodes of mania or hypomania would have cognitive deficits, 
including in reversal learning, vs. those BD-NOS participants with sub-threshold episodes and 
TDCs. N = 175 participants (BD-I = 81, BD-II = 11, BD-NOS = 28, TDC = 55) completed 
Cambridge Neuropsychological Automated Testing Battery (CANTAB) tasks. A priori analyses of 
the simple reversal stage of the CANTAB intra-/extra-dimensional shift task showed that 
aggregated BD-I/II participants required significantly more trials to complete the task than either 
BD-NOS participants with sub-syndromal manic/hypomanic symptoms or than TDCs. BD 
participants across sub-types had impairments in sustained attention and information processing 
for emotionally valenced words. Our results align with prior findings showing that BD-I/II youths 
with distinct episodes have specific alterations in reversal learning. More broadly, our study 
suggests that further work is necessary to see the interaction between neurocognitive performance 
and longitudinal illness course. Additional work is required to identify the neural underpinnings of 
these differences as targets for potential novel treatments, such as cognitive remediation.
Keywords
Bipolar disorder; Child; Adolescent; Cognitive performance; Reversal learning
Introduction
Greater understanding of the cognitive function associated with bipolar disorder (BD) in 
children and adolescents is crucial for two reasons. First and foremost, we need better 
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understanding of the biological underpinnings of cognitive dysfunction in BD youths, given 
studies showing associated academic difficulties [1]. Second, from a broader perspective, 
many of the symptoms of mania and depression reflect cognitive dysfunction, such as 
distractibility and increased goal-directed activity and pleasure seeking in mania, and also 
impaired concentration and decision making in depression. Greater biological understanding 
of these cognitive alterations could be used to develop biological and behavioral markers for 
BD. In turn, cognitive biobehavioral markers of BD could augment clinical history, resulting 
in better, more specific, and earlier diagnosis of BD. These markers could result in brain-
based treatment approaches for BD in children and adolescents, such as computer-assisted 
cognitive remediation. This approach of biological markers transforming diagnostic and 
treatment strategies is akin to the approach which has been so successful in transforming the 
diagnosis and treatment of childhood leukemia from 100 % mortality to now having a 5-year 
survival of over 90 % [2].
Moreover, the need for such markers to improve diagnostic specificity is highlighted by 
studies demonstrating that increasing numbers of youths are being diagnosed with BD. For 
example, studies have shown that from the mid-1990s to the mid-2000s, rates of children 
and adolescents in the United States (US) discharged from psychiatric hospitals with a 
diagnosis of BD grew from less than 10–20 % [3]. This rise was not restricted to child 
psychiatrists, as during a similar time period, rates of children seen in the US for outpatient 
visits by providers of all specialties increased 40-fold (not 40 %) [4]. This was not restricted 
to the US, as another study found a 68.5 % rise in German youths hospitalized for BD that 
was out of proportion to general trends in mental illness [5]. Without such markers, the field 
is left with the unanswerable question of whether this represents better diagnosis of a serious 
problem, over-or misdiagnosis, or both.
Towards that end, studies have shown that youths with BD have impaired neurocognitive 
performance in several domains, including attention [1], memory [6, 7], emotional face 
processing [8–10], and reversal learning and cognitive flexibility [11–16]. In particular, 
cognitive flexibility—defined as the ability to adapt one's thinking and behavior in response 
to changing rewards—is relevant to BD via its link to functionally impairing irritability [17, 
18]. Children with reduced cognitive flexibility may be less able to adapt to social feedback 
and rewards, such as praise or reprimand from teachers, parents or peers. This may result in 
frustration—defined as the emotional state occurring when an individual performs an action 
in the expectation of a reward but does not receive a reward—leading to the observable 
behavior of irritability [19–23].
Cognitive flexibility can be studied in the lab using reversal learning tasks, whereby 
participants use trial-and-error learning to determine which of two stimuli is initially 
rewarded, and then they must adapt when the previously rewarded stimulus is now punished. 
Children and adolescents meeting Leibenluft et al.'s criteria for “narrow-pheno-type” BD 
type I or II by virtue of having elevated, expansive mood satisfying DSM-IV-TR's duration 
criteria manic or hypomanic episodes have impaired reversal learning vs. typically 
developing controls (TDCs) without psychopathology themselves and in their first-degree 
relatives. This has been shown on two different reversal learning tasks, including the simple 
reversal stage of the Cambridge Neuropsychological Testing Automated Battery (CANTAB, 
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Cambridge, UK) intra-dimensional/extra-dimensional shift task (IDED) and the probabilistic 
response reversal task (PRR) developed by James Blair, Ph.D. [11–14]. Studies have also 
shown that narrow-phenotype BD youths have the exact opposite functional magnetic 
resonance imaging (fMRI) neural activation during reversal learning than TDCs [15]. 
Moreover, two studies have shown that BD youths had distinct behavioral and neural 
alterations during reversal learning vs. those with a functionally impairing course of chronic 
non-episodic irritability meeting Leibenluft's criteria for severe mood dysregulation (SMD) 
which formed the basis for DSM-5′s “Disruptive Mood Dysregulation Disorder” (DMDD) 
[13, 16]. Taken as a whole, this suggests that BD youths with distinct episodes of mania/
hypomania may have specific brain/behavior alterations in reversal learning and cognitive 
flexibility, but this has not been evaluated in sub-threshold BD-NOS participants.
While important, most of these studies focus on children with BD type I (BD-I) or type II 
(BD-II), without examining neurocognitive function in children with sub-threshold 
presentations of BD [24]. Addressing BD “Not Otherwise Specified” (BD-NOS) is key 
because: (a) these conditions are on a continuum with BD-I and -II in terms of severity of 
mood symptoms, familial loading, and associated clinical features [25, 26]; (b) statistical 
models indicate that mania, hypomania, and normal behavior fall along a continuum [27]; 
(c) NOS can be highly impairing; and (d) they appear to be more common than bipolar I or 
II in both clinical and epidemiological samples [28]. The Course and Outcome of Bipolar 
Youth (COBY) study is a large, multi-site study that was established to address this unmet 
need for greater knowledge about how sub-syndromal BD-NOS was the same, or was 
different, from those with full-duration mania and hypomania (BD-I and BD-II, 
respectively). COBY operationalized and validated criteria for BD-NOS to include having a 
distinct period(s) of abnormally elevated, expansive or irritable mood that did not meet full 
DSM-IV criteria for mania or hypomania, plus: (1) at least two DSM-IV manic symptoms 
(three if the mood is irritable only) that were clearly associated with the onset of abnormal 
mood; (2) clear change in functioning; (3) mood and symptoms present for a significant part 
of the day (minimum of 4 h); and (4) a minimum of 4 days (not necessarily consecutive) 
meeting these mood, symptom, duration, and functional change criteria over the participant's 
lifetime [29, 30]. In distinction to COBY BD-NOS criteria, SMD criteria specified that 
children could not have “cardinal” features of mania, such as elevated/expansive mood, 
grandiosity, or episodically decreased need for sleep. Similarly, DMDD criteria specified 
that children could not have experienced a period longer than 1 day when symptom criteria 
except for duration for a manic or hypomanic episode were met. COBY publications 
indicate that with prospective longitudinal follow-up, progressive numbers of BD-NOS 
participants develop full-duration BD-I and BD-II (up to 45 % at 5 years), and this 
conversion is most strongly associated with first- and second-degree history of mania or 
hypomania, but not associated with lifetime inpatient psychiatric hospitalization [31]. 
However, to date, no studies have examined cognitive performance among BD youths with 
distinct episodes of mania/hypomania compared to those with a more sub-syndromal 
presentation, such as those meeting COBY BD-NOS criteria.
To address this gap in knowledge, we present the first known large-scale study of 
neurocognitive function in children and adolescents with phenotypes of pediatric BD, 
including BD-I, II, and BD-NOS. These data were collected under the auspices of the 
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Course and Outcome of Bipolar Youth (COBY) study, a multi-site longitudinal 
phenomenology study that began administering CANTAB cognitive performance testing in 
2007 during its second 5-year funding period. We sought to test the a priori hypothesis that 
BD-I and BD-II youths with full threshold episodes of mania or hypomania would have 
reversal learning deficits compared to those BD-NOS with sub-threshold episodes and also 
compared to TDC participants on the CANTAB IDED simple reversal stage. Based on data 
indicating that episodes matter—i.e., behavioral and brain imaging studies showing that 
youths with distinct episodes of mania/hypomania (BD-I and -II) had reversal learning 
deficits—we hypothesized that reversal learning deficits would categorically distinguish BD-
I/II youths from BD-NOS youths, rather than BD-NOS youths being intermediate but 
significantly different from both BD-I/II and TDC participants [12, 14–16, 32]. Similar four-
group analyses evaluated the specificity of these data to BD-I, II, and NOS participants vs. 
TDC participants. We also examined broader neuropsychological performance using 
additional CANTAB tasks of visuospatial memory, working memory, sustained attention, 
and emotional bias in information processing. On these more general tasks, we hypothesized 
that BD-I and BD-II youths with full threshold episodes of mania or hypomania would have 
reversal learning deficits vs. those BD-NOS with sub-threshold episodes and vs. TDC 
participants [33]. Lastly, we examined the association between neurocognitive performance 
and mood symptomatology before and during the assessment.
Methods
BD participants and intake procedures
All participants and their parents provided written informed assent and consent, respectively, 
in the Institutional Review Board approved study at each participating site. As described 
elsewhere, COBY study sites included Brown University, University of Pittsburgh, and 
University of California Los Angeles [29, 34]. Children and adolescents ages 7–18 years old 
with BD-I, BD-II, or BD-NOS were recruited from outpatient clinics (67.6 %), inpatient 
units (14.3 %), advertisements (13.3 %), and referrals from other mental health professionals 
(4.8 %) [30].
Inclusion criteria for BD-I and BD-II participants consisted of meeting DSM-IV criteria. 
Since DSM-IV criteria for BD-NOS were vague, the COBY study operationalized BD-NOS 
inclusion criteria as failing to meet DSM-IV criteria for BD-I or BD-II but having a distinct 
period(s) of abnormally elevated, expansive or irritable mood, plus: (1) at least two DSM-IV 
manic symptoms (three if the mood is irritable only) that were clearly associated with the 
onset of abnormal mood; (2) clear change in functioning; (3) mood and symptoms present 
for a significant part of the day (minimum of 4 h); and (4) a minimum of 4 days (not 
necessarily consecutive) meeting these mood, symptom, duration, and functional change 
criteria over the participant's lifetime [29, 30].
The age of onset for BD-NOS was defined as when the participant first met DSM-IV criteria 
for a Major Depressive Episode or COBY criteria for BD-NOS, with a minimum age of 
onset set at age 4. The requirement of distinct episodes of mood change with associated 
manic/hypomanic symptoms differs from Leibenluft's SMD criteria, which require chronic, 
non-episodic irritable mood and symptoms of hyperarousal found in ADHD [20]. COBY 
Dickstein et al. Page 5
Eur Child Adolesc Psychiatry. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
study data demonstrate that BD-NOS youths resemble BD-I and BD-II youths with respect 
to functional impairment, psychiatric comorbidity, suicidality, and family history, suggesting 
that COBY BD-NOS criteria identify youths who have a sub-threshold presentation of BD, 
rather than another illness [29–31, 35–37]. However, this is the first examination of 
neuropsychological performance data from the COBY study.
As stated in prior COBY publications, participants were also included if they had either a 
chronologically primary BD with secondary substance abuse disorder or with mild comorbid 
Asperger's Disorder or Pervasive Developmental Disorder (PDD) NOS as long as their mood 
symptomatology was clearly episodic and best accounted for by the BD diagnosis, rather 
than either secondary substance abuse or secondary PDD-spectrum illness [29, 34].
Exclusion criteria for all groups were current or lifetime diagnoses of schizophrenia, mental 
retardation, autism, and mood disorders secondary to substance abuse, medical conditions, 
or use of medications. In addition, for the CANTAB analyses reported here, COBY 
participants were excluded if their IQ was less than 75 to avoid the potential confound of 
intellectual disability on our results.
Prior to study participation, informed consent and assent was obtained from a parent or 
guardian and child, respectively. Participants were assessed at intake with a semi-structured 
interview administered to the youth and a parent/caregiver administered by a trained 
research clinician.
Mood symptom severity employed the 12-item KSADS depression rating scale (DRS) and 
the KSADS Mania Rating Scale (MRS) [38] for the most severe week in the month prior to 
the intake assessment and for the most severe week lifetime [39]. Per the KSADS 
instructions, mood symptoms common to other diagnoses (i.e., distractibility) were only 
rated as present in the mood sections if they intensified with the onset of abnormal mood to 
avoid double-counting these symptoms. Non-mood psychiatric disorders were assessed 
using the Schedule for Affective Disorders and Schizophrenia for School-Age Children, 
Present and Lifetime Version (KSADS-P/L) [40]. KSADS interviews also ascertained 
current and past history of pharmacological treatments.
Research clinicians with bachelors, masters, or doctoral degrees in mental health related 
fields conducted all interviews. Interviewers were not blind to participants’ prior diagnoses. 
Case conferences with one of the principal or co-investigators reviewed all available 
information before reaching a consensus diagnosis. Reliability was assessed using 
audiotapes of randomly selected interviews. The reliability of differentiating BD-NOS from 
BD-I/II and no BD at the intake assessment was κ = 0.74, based on ratings of 13 different 
audiotaped interviews by an average of 6 raters per interview (range 5–7).
Intellectual functioning was assessed using the vocabulary and matrix reasoning subtests of 
the Wechsler Abbreviated Scales of Intelligence (WASI; The Psychological Corporation, 
1999).
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Longitudinal assessment procedures
Changes in psychiatric symptomatology and treatment occurring proximally to CANTAB 
testing after intake were assessed: (a) using the MRS and DRS for mania and depression, 
respectively, 2 days prior to CANTAB testing, (b) gathering information about medication 
and substance use 24 h prior to CANTAB testing.
Longitudinal changes in psychiatric symptomatology between intake and CANTAB testing 
were tracked on a week-by-week basis with the Psychiatric Status Rating (PSR) scale of the 
Longitudinal Interval Follow-up Evaluation (LIFE) [41]. Information about change points in 
the course of illness during the follow-up period is gathered by interview, and then translated 
into numerical PSR scores liked to DSM-IV criteria. For mood disorders, the PSR scores 
are: 1–2 no/minimal symptoms, 3–4 varying levels of clinically relevant sub-threshold 
symptoms, and 5–6 for full criteria. Manic symptomatology that did not meet full DSM-IV 
criteria for a Manic or Mixed Episode was rated on the Hypomania PSR line. A consensus 
score for each PSR line was determined after interviewing participants and parent/caregiver 
informant, and reviewing available medical records. Duration and number of episodes were 
recorded using a grid adapted from the Mania/Hypomania/Mixed State duration table of the 
KSADS-P Mania section.
Kendall's W statistic of the reliability for the LIFE follow-up assessment in euthymic, full 
threshold, and sub-threshold mood states was ≥0.75. The reliability of the PSR for 
diagnosing mood episodes over a follow-up interval was based on ratings from 36 different 
interviews by an average of 7.6 raters (range 4–10) per interview; κ = 0.62 for diagnosis of a 
Manic, Mixed, or Hypomanic Episode, and κ = 0.62 for diagnosis of a Major Depressive 
Episode.
Exposure to psychosocial and pharmacological treatments was also ascertained through the 
LIFE. Medication data were grouped by class [e.g., lithium, anti-epileptic drug (e.g., 
valproate, carbamazepine, etc.), or anti-psychotics (e.g., risperidone, quetiapine, etc.)] and 
weekly exposure was considered a dichotomous variable (yes/no) for each class. 
Psychosocial treatments were examined as a dichotomous variable (yes/no) and divided into 
three categories of intensity for each week: inpatient/residential treatment, intensive services 
(e.g., in-home, partial hospitalization), and standard outpatient services.
Typically developing control (TDC) participants
Since the COBY study did not involve recruiting a sample of TDC children without DSM 
psychopathology, to ascertain how CANTAB performance differed among BD sub-types and 
also from typical development, we utilized CANTAB data collected from TDC participants 
enrolled in other studies at participating COBY sites. Specifically, we utilized CANTAB 
data from TDC participants in the Longitudinal Assessment of Manic Symptoms (LAMS) 
study (total N = 32 including UPMC N = 16, Case-Western N = 11, University of Cincinnati 
N = 5), which administered the following CANTAB tests: Intra-Dimensional/Extra-
Dimensional Set-shifting task (IDED), Rapid Visual Information Processing (RVP), 
Affective Go/No Go (AGN) [42]. We also utilized CANTAB data from TDC participants at 
Bradley Hospital/Brown University's Pediatric Mood, Imaging, and NeuroDevelopment 
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(PediMIND) Program (N = 23), which administered the following CANTAB tests: IDED, 
Pattern Recognition Memory (PRM), Spatial Span (SSP), and AGN.
TDC inclusion criteria at Bradley Hospital/Brown University were: age 7–17 years, WASI 
FSIQ >75; no current or lifetime psychiatric illness or substance abuse/dependence among 
the TDC child and their first-degree relative as determined by the KSADS-PL administered 
by graduate level clinicians with established inter-rater reliability (κ >0.85).
TDC inclusion criteria for the LAMS study (University of Pittsburgh, Case-Western Reserve 
University, University of Cincinnati) were: age 10–16 years, no current or lifetime 
psychiatric illness or substance abuse/dependence among the TDC, no history of 
developmental delay or learning disability, the TDC's first-degree relatives could not have a 
mood disorder, and the TDC's second-degree relatives (i.e., grandparents, aunts, uncles, and 
half-siblings) could not have a history of mania, hypomania, or psychosis [42]. TDC 
participants were not selected based on task performance.
CANTAB testing
CANTAB testing was administered in an outpatient research setting to BD and TDC 
participants. CANTAB tasks were not administered to participants evidencing substance 
intoxication, sedation, or who refused testing. We administered the following CANTAB 
tests:
Intra-dimensional/extra-dimensional (ID/ED) shift—This set-shifting task mirrors 
the Wisconsin Card Sorting Task. Stimuli are presented in pairs during 9 stages, each of 
which requires the participant to successfully complete 6 trials in a maximum of 50 
attempts, or else the test is discontinued. Participants use feedback during trial-and-error 
learning to determine which of two stimuli shapes is rewarded—i.e., purple square rather 
than purple circle. Stage 2 reverses the stimulus/reward association—i.e., purple circle rather 
than purple square rewarded. White line designs are added as distracters during stage 3–9. 
However, during stages 3–7, reinforcement depends only on shape, with line design being 
irrelevant. Stage 6 is known as the “intra-dimensional shift” because new line/shapes replace 
the old, but choice of the correct shape continues to determine reinforcement. Stage 8 is the 
“extra-dimensional” shift because it is the first stage when the previously irrelevant construct
—i.e., white line design—is rewarded. Outcome data include stages completed, errors, and 
trials for each stage, for all trials before the ED shift (i.e., stages 1–7 “pre-ED shift”), and 
those at and after the ED shift.
Pattern recognition memory (PRM)—Participants first view 12 shapes one at a time, 
and then, pairs of shapes are presented, one novel and one previously presented. Participants 
must identify the previously presented, rather than novel, shape within the pair. Outcome 
data include number and percent correct and mean latency to correct responses.
Spatial memory span (SSP)—This test of working memory is modeled after the Corsi 
Block Test. Participants watched squares on the screen change colors one at a time from 
white to a different color. Participants then touched the squares on the screen in the same 
sequence in which they changed colors. The number of blocks increases from 2 to 9 across 
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trials. Outcome data include length of memory span, total errors (i.e., number of times the 
participant selected an incorrect box), and total usage errors (i.e., number of times the 
participant selected a box not in the sequence being recalled).
Rapid visual information processing (RVP)—This task evaluated sustained attention 
akin to the continuous performance task. During RVP, a white box appears in the center of 
the computer screen, inside of which digits from 2 to 9 appear in pseudo-random order at the 
rate of 100 digits per minute. Participants are asked to press a button whenever they detect a 
specified target sequence—i.e., press the button when you see 2-4-6). Outcome data include 
A′ [signal detection theory measure of sensitivity to errors, regardless of error tendency—
i.e., how good the participant is at detecting target sequence (range 0.00–1.00)], B′ [signal 
detection measure of strength of trace required to elicit a response—i.e., tendency to respond 
regardless of whether target sequence is present or not (range −1.00 to 1.00)], and 
probability (i.e., change of making specific response) of hits, misses, false alarms, and 
rejections.
Affective Go/No Go (AGN)—This test evaluates information processing for positive and 
negative words. The task consists of several blocks, each of which presents a series of words 
from two of three affective categories: (1) positive (e.g., joyful), (2) negative (e.g., hopeless), 
and (3) neutral (e.g., element). Participants press the button whenever they see a word 
matching a target word category—i.e., press the button if you see positive words. Outcome 
data include latency, commission errors (incorrect response to a distractor stimulus), and 
omission errors (incorrect response to a target stimulus).
Analytic strategy
Analyses used Statistical Package for Social Sciences (SPSS) version 17. Our analytic 
strategy attempted to balance the potential for Type I and Type II errors in this study, the first 
to use the CANTAB to compare neurocognitive performance in different sub-types of 
pediatric BD vs. TDCs. All analyses used Bonferroni correction in setting significance 
threshold to minimize multiple comparisons issues.
Our primary analysis tested our a priori hypotheses about simple reversal learning deficits by 
evaluating simple reversal learning stage performance between BD-I or BD-II participants 
grouped together, since they share the phenotype of meeting DSM-defined episodes of 
mania or hypomania, vs. BD-NOS and TDC participants. Specifically, we conducted an 
analysis of variance (ANOVA) with the independent variable being group (BD-I/II, BD-
NOS, TDC) and two dependent variables from the IDED task stage 2 simple reversal (errors 
and trials). We also conducted 4-group analyses to evaluate potential differences between 
BD-I, BD-II, BD-NOS, and TDC participants though recognizing that these may be 
somewhat underpowered.
Additional analyses evaluated CANTAB tasks tapping other neurocognitive domains, 
including visuospatial working memory (PRM), working memory (SSP), sustained attention 
(RVP), and information processing for positive and negative words (AGN). We conducted 
separate ANOVAs for each CANTAB task, using the participant groupings as above (i.e., 
BD-I/II, BD-NOS, TDC and also BD-I, BD-II, BD-NOS, and TDC).
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Secondary analyses examined potential effects of medication, mood state effects, and 
psychiatric comorbidity among BD participants, since such analyses were not applicable to 
TDC participants as they did not have psychopathology or take psychotropic medication. 
Medication effects at testing were evaluated via MANOVAs, with fixed factors of group 
(BD-I/II vs. BD-NOS and also separate analyses aggregating all participants) and yes/no 
currently taking specific medication categories and dependent factors of CANTAB 
performance. To evaluate mood state, we conducted MANOVAs to test the effect on 
CANTAB data of having threshold/sub-threshold vs. no symptoms of either mania (KSADS-
MRS) or depression (KSADS-DRS) during the 2 days prior to CANTAB testing. We also 
evaluated Pearson correlations between CANTAB task data and percent weeks with either 
no/minimal mood symptoms or full threshold mood symptoms at 2, 6, and 12 months prior 
to CANTAB testing. Psychiatric comorbidity for PDD and ADHD was evaluated via 
MANOVAs, with fixed factors of group (BD-I/II vs. BD-NOS and also separate analyses 
aggregating all participants) and yes/no currently affected by PDD or ADHD (analyzed 
separately) and dependent factors of CANTAB performance.
Results
Participants
There were no between-group differences among BD-I (N = 81), BD-II (N = 11), and BD-
NOS (N = 28), or TDC (N = 55) participants with respect to age, full-scale IQ, or sex even 
when BD-I and BD-II participants were aggregated. At testing, there was a between-group 
difference in participants taking lithium, with more BD-I participants (25.9 %) taking 
lithium than BD-II (0 %) or BD-NOS (10.7 %; χ2 = 6.04, p = 0.05). There were no 
between-group differences in number of participants taking other medication classes (Table 
1).
There were no significant between-group differences in mania (MRS χ2 = 2.68, p = 0.61) or 
depression (DSR χ2 = 3.44, p = 0.49) ratings 2 days prior to and including the CANTAB 
testing. There was a between-group difference in mood episode status during the week prior 
to testing (χ2 = 18.16, p = 0.006), with more BD-I participants rated as being in sub-
threshold depression (50.6 %) than other groups and more BD-II participants rated as being 
euthymic (54.5 %) or full hreshold major depressive episode (27.3 %) than the other groups.
CANTAB results
Primary analysis: reversal learning
First, we tested our a priori hypothesis that BD youths with full threshold DSM-IV episodes 
of mania and hypomania (i.e., BD-I and BD-II) would have worse performance on the 
simple reversal stage of the IDED task vs. BD-NOS and TDC participants, we found a 
significant multivariate effect of group (Wilks’ Lambda F[6,340] = 2.69, p = 0.01) and 
significant between-subjects effect of group on IDED simple reversal stage total trials 
(F[3,171] = 3.97, p = 0.009) but not errors (F[3,171] = 1.70, p = 0.17). Post hoc pairwise 
analyses showed that this was driven by BD-I participants requiring significantly more 
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IDED simple reversal trials than TDCs (BD-I 9.52 ± 5.12; TDC 7.56 ± 1.54; p = 0.02), but 
not than BD-NOS (7.46 ± 1.20; p = 0.07) or BD-II (8.45 ± 2.51; p = 1.0).
When BD-I and BD-II participants were aggregated based on both having distinct episodes 
of mania/hypomania, we found a significant multivariate effect of group (Wilks’ Lambda 
F[4,342] = 3.83 p = 0.005) and significant between-subjects effect of group on IDED simple 
reversal stage total trials (F[2,172] = 5.56, p = 0.005) but not errors (F[2,172] = 2.12, p = 
0.12). Post hoc pair-wise analyses showed that this was driven by BD-I/II participants 
requiring significantly more IDED simple reversal trials than BD-NOS (BD-I/II 9.39 ± 4.89; 
BD-NOS 7.46 ± 1.20; p = 0.05) and also than TDCs (TDC 7.56 ± 1.54; p = 0.01) (Fig. 1).
Neither result was driven by a site effect among TDC participants, as MANOVAs of IDED 
performance did not show a significant multivariate effect of site.
Primary analysis: additional CANTAB tasks
We then tested the effect on different BD phenotypes on neuropsychological performance in 
the following domains: visuospatial working memory (PRM), working memory (SSP), 
sustained attention (RVP), and information processing for positive and negative words 
(AGN). Comparing BD participants with full threshold episodes (i.e., BD-I and BD-II) to 
those with sub-threshold symptoms (i.e., BD-NOS), there were significant multivariate 
effects for RVP (F[12,272] = 17.60, p < 0.001) and AGN (F[6,338] = 2.19, p = 0.04), but not 
for SSP or PRM, or the IDED omnibus measures (Table 2).
On the RVP, we found a significant between-group difference on RVP A′ (F[2,141] = 30.28, 
p < 0.001), total correct rejections (F[2,141] = 23.12, p < 0.001), and probability of hit 
(F[2,141] = 32.23, p < 0.001). Post hoc pairwise analyses demonstrated that these were all 
driven by worse performance among each BD group vs. TDCs, but not compared to one 
another (all p < 0.001).
On the AGN, there were no between-group differences on total commissions (F[2,171] = 
1.70, p = 0.19), total omissions (F[2,171] = 1.97, p = 0.14), or mean correct latency 
(F[2,171] = 0.66, p = 0.52).
Similarly, analyzing our data as four separate groups (i.e., BD-I, BD-II, BD-NOS and TDC 
participants), we found significant multivariate effects of group on the RVP (Wilks’ Lambda 
F[18,382] = 10.78, p < 0.001), but not the AGN, SSP, or PRM tasks, or the IDED omnibus 
measures (Table 3).
On the RVP, we found a significant between-group difference on RVP A′ (F[3,140] = 20.07, 
p < 0.001), total correct rejections (F[3,140] = 15.37, p < 0.001), and probability of hit 
(F[3,140] = 21.50, p < 0.001). Post hoc pair-wise analyses demonstrated that these were all 
driven by worse performance among each BD group vs. TDCs, but not vs. one another (all p 
< 0.001).
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Secondary analyses: medication effects
We conducted MANOVAs to evaluate potential medication effects on our data, with fixed 
factors of group and yes/no currently taking specific medication classes, and dependent 
factors of CANTAB performance on measures previously shown to have between-group 
differences in our primary analyses (i.e., IDED simple reversal trials; RVP A′, total correct 
rejections, and probability of hit). However, there were no significant multivariate tests for 
group × medication interactions for lithium, anti-psychotic, anti-epileptic drug, anti-
depressant, ADHD stimulant medications, and benzodiazepines.
Secondary analyses: mood state
To test potential effects of mood status on neuropsychological performance, we first 
examined potential relationships between IDED simple reversal stage trials and errors from 
our primary analysis and mood status. We conducted MANOVAs to evaluate potential mood 
effects, with fixed factors of group and threshold/sub-threshold depression (KSADS-DRS) 
or mania (KSADS-MRS) for the 2 days prior to CANTAB testing. However, multivariate 
tests of group × mood status were not significant, whether BD participants were grouped 
(BD-I/II vs. BD-NOS) or not (BD-I vs. BD-II vs. BD-NOS). Analyses for the RVP (RVP A
′, total correct rejections, and probability of hit) were also not significant.
To further probe the relationship between mood and cognitive performance, we examined 
Pearson correlations between CANTAB measures where there were between-group 
performance differences (IDED simple reversal trials; RVP A′, total correct rejections, and 
probability of hit) and percent weeks with either no/minimal or full threshold mood 
(including depression and mania) symptoms at 2, 6, and 12 months prior to CANTAB 
testing. However, no correlation was significant when corrected for multiple comparisons 
within the BD-I, BD-II, or BD-NOS groups.
Secondary analyses: psychiatric comorbidity
We conducted secondary analyses to probe potential effects of psychiatric comorbidity. With 
regard to PDD-spectrum illness, excluding 6/81 BD-I, 2/11 BD-II, 0/28 BD-NOS and 0/55 
TDCs, all of our between-group CANTAB performance differences from our primary 
analyses remained significant (IDED simple reversal trials; RVP A′, total correct rejections, 
and probability of hit). Additionally, we found a between-group difference in IDED simple 
reversal errors was also significant whether BD-I/II was grouped (F[2,164] = 5.0, p = 0.008) 
or not (F[2,163] = 3.58, p = 0.02) driven by significant differences between BD-I vs. TDC (p 
= 0.03) or BD-I/II vs. TDC (p = 0.02). With regard to ADHD, when we restricted our BD 
participants to those without comorbid ADHD (33/81 BD-I, 9/11 BD-II, 12/28 BD-NOS) 
and all TDCs, all of our between-group CANTAB performance differences from our primary 
analyses remained significant (IDED simple reversal trials; RVP A′, total correct rejections, 
and probability of hit).
Discussion
Our study, the first large-scale study of cognitive performance in children with different sub-
types of BD, demonstrates that children and adolescents with distinct full DSM-IV duration 
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episodes of mania or hypomania have evidence of impairment on measures of cognitive 
flexibility (IDED simple reversal stage), sustained attention (RVP), and information 
processing for emotionally valenced words (AGN). Impaired reversal learning among BD 
youths with distinct episodes of mania/hypomania is an important and independent 
replication of some of the prior data showing reversal learning deficits in narrow-phenotype 
BD-I/II youths from Leibenluft's NIMH sample [11–16]. Moreover, RVP deficits in 
sustained attention and AGN deficits in information processing of emotionally valenced 
words overall found among all BD youths regardless of sub-type vs. controls are an 
important finding suggesting that on some cognitive domains, these BD youths may be more 
similar than not. Further study is warranted to determine the neural basis, longitudinal 
trajectory, and potential improvement via targeted treatment, including medication, 
psychotherapy, and cognitive remediation.
Our finding supporting our a priori hypothesis that BD-I/II participants required more trials 
than BD-NOS participants to complete the simple reversal stage is interesting given ongoing 
work on reversal learning and cognitive flexibility in pediatric BD. Specifically, a line of 
research has shown that children and adolescents meeting Leibenluft et al.'s research 
definition for “narrow-phenotype” pediatric BD type I/II via distinct episodes of mania or 
hypomania requiring euphoria to meet the DSM “A” mood criteria have behavioral deficits 
on computerized tasks of reversal learning and cognitive flexibility [20]. Narrow-phenotype 
BD youths make more errors and require more trials to complete the CANTAB IDED simple 
reversal stage than TDC youths without psychiatric illness [11], and a separate study not 
only replicated this finding in an expanded sample of BD and control participants, but also 
showed that BD youths had this deficit compared to a group of SMD youths with chronic 
non-episodic irritability, persistent negative mood, and ADHD-like symptoms of 
hyperactivity [13]. Moreover, narrow-phenotype BD youths have behavioral deficits on the 
probabilistic response reversal task (PRR) that adds probabilistic feedback, whereby the 
preferred stimulus is mostly rewarded, but sometimes punished, and then this stimulus/
reward association is reversed. Narrow-phenotype BD youths have been shown to have 
impaired PRR performance vs. control participants in one study [12], and impaired PRR 
performance vs. youths with either major depressive disorder, anxiety disorders, SMD, or 
TDCs in another study [14]. Moreover, two recent event-related fMRI studies suggest that 
narrow-phenotype BD youths have specific brain alterations mediating this reversal learning 
deficits, the first vs. TDC participants [15] and the second vs. SMD participants [16]. Our 
operational definition of bipolar disorders emphasized distinct episodes, consistent with the 
focus on episodicity in the Leibenluft narrow definition as well as in DSM-5 and the 
recommendations of the International Society for Bipolar Disorders [43, 44]. Taken as a 
whole, brain/behavior alterations underlying reversal learning and cognitive flexibility show 
some promise as a potential future biobehavioral marker of BD youths with distinct episodes 
of mania, possibly serving as target for future intervention, marker of treatment response, or 
of the diagnosis itself.
Several studies have evaluated reversal learning in adults with BD. For example, in two 
separate studies, Clark and colleagues first demonstrated first that BD adults when manic 
had significantly impaired reversal learning as indexed by the sum of errors made during all 
reversal stages of the CANTAB IDED task vs. control adults [45]. They then showed in a 
Dickstein et al. Page 13
Eur Child Adolesc Psychiatry. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
separate study similar significant impairments in reversal learning among euthymic BD 
adults [46]. More recently, Roiser et al. found that unmedicated, depressed BD adults 
(primarily with BD-II) had reversal learning deficits vs. control adults using a probabilistic 
reversal learning task designed to increase task difficulty via inconsistent feedback [47]. 
Although some studies have failed to find between-group differences in reversal learning 
among BD adults, such as that of Rubinzstein [48], greater understanding of developmental 
alterations in reversal learning in BD, using longitudinal assessment as BD and control 
children become adults, seems warranted to determine how BD results in a potential 
divergence from this developmental trajectory.
Our RVP results showing that BD participants regardless of sub-type have impaired 
sustained attention align with prior work demonstrating attention impairments in BD. For 
example, Clark et al. showed that euthymic BD adults had impaired RVP performance vs. 
control adults even after controlling for mild affective symptoms [46]. Moreover, this deficit 
was related to the BD participants’ illness progression. In a four-group comparison of adults 
with BD (depressed, euthymic), unipolar major depressive disorder, or controls without 
psychopathology, Maalouf et al. showed that groups of euthymic and depressed BD adults 
made more RVP errors than controls, but did not differ from one another or from those with 
unipolar major depressive disorder [49]. For clinicians and researchers alike, disentangling 
whether impaired attention is an integral part of the brain/behavior alterations in BD itself, 
or whether they reflect comorbid, co-occurring, but distinct pathology related to ADHD, is 
an important question. This question is worthy of further research because data support both 
possibilities [50–53], and it has important implications for diagnosis and also for treatment.
More broadly, our work raises two important issues. First, we note that, except for 
confirming our a priori hypothesis that reversal learning would differ in BD-I/II vs. BD-NOS 
participants, our other analyses failed to find differences that were specific and distinguished 
one BD subgroup from another. While wishing to avoid potential type II error by over-
interpreting this lack of difference including fewer BD-II participants, we note that this lack 
of differences between BD-I, II, and NOS participants aligns with numerous other findings 
from the COBY study. This includes data indicating similar rates of functional impairment, 
psychiatric comorbidity, suicidality, and family history between BD-I, II, and NOS 
participants, suggesting that COBY BD-NOS criteria identify youths who have a sub-
threshold presentation of BD rather than that they have a different illness [29–31, 35–37]. 
Second, we note that while our a priori reversal learning analyses suggest that youths with 
distinct episodes of mania or hypomania (BD-I or -II) differ from those with sub-threshold 
symptoms (BD-NOS), that is not to suggest that COBY BD-NOS criteria identify the same 
youths as those of Leibenluft's SMD criteria. In particular, we note that COBY BD-NOS 
participants can and do have episodes, although brief, involving euphoria and irritability 
[37], whereas both distinct episodes and euphoria are exclusionary from SMD and DMDD 
criteria [20].
Our work has several important limitations, including the lack of a COBY-recruited TDC 
group, limited number of BD-II participants, ongoing medication use, and mood-state issues. 
First, as a longitudinal phenomenology study of BD in children and adolescents, COBY did 
not recruit a cohort of control children and adolescents. While imperfect, given the need to 
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advance our understanding of cognitive dysfunction in BD youths, we have attempted to use 
TDC participants completing CANTAB testing at COBY-participating sites in non-COBY 
studies to control for typical development. Going forward, there is a clear need for a better 
solution, which would likely involve enrolling BD and TDC participants at every site. 
Second, we had relatively few BD-II participants compared to those with BD-I or BD-NOS. 
To address this concern, and based on prior work showing that BD youths with distinct full-
duration episodes of mania or hypomania have impaired reversal learning deficits, our 
primary a priori analyses focus on aggregating BD-I and BD-II participants vs. BD-NOS 
participants. However, additional study of the neurocognitive performance of BD-II youths 
is warranted. Last, most of our participants were taking their usual outpatient psychiatric 
medications when tested. Given that COBY is not a treatment study, it would have been 
unethical to withdraw them from such medications just for computer testing. Our data 
demonstrated comparable distribution of psychotropic medications across diagnostic groups 
making it less likely that our results were biased by a particular type of medication. 
Similarly, we did not find significant relationships between mood state and CANTAB 
performance. Nevertheless, further examining the potential impact of both psychotropic 
medications and mood state on neurocognitive performance in BD youths is an important 
area of future study.
Conclusion
In sum, our study begins to shed light on neuropsychological performance in children and 
adolescents suffering from different sub-types BD. Our study suggests that BD-I and BD-II 
participants have greater difficulty on reversal learning tasks than BD-NOS and TDC 
participants, aligning with other studies showing similar impairments in youth with distinct 
episodes of mania. We also found deficits in sustained attention and information processing 
for emotionally valenced words across BD sub-types vs. TDC participants. Further work is 
necessary to see the interaction between neurocognitive performance and longitudinal illness 
course and development as these COBY BD participants become young adults, and to 
evaluate neural underpinnings of these differences.
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Fig. 1. 
Intra-dimensional/extra-dimensional (IDED) shift task simple reversal trials and errors
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Table 1
Demographics by group
Group BD-I (N = 81) BD-II (N = 11) BD-NOS (N = 
28)
TDC (N = 
55)
Age 14.0 ± 2.4 14.7 ± 2.1 13.5 ± 2.3 14.2 ± 2.3 F(3,171) = 0.80; p 
= 0.49
Female/male 31/50 4/7 9/19 26/29 X2 = 2.09; p = 
0.55
IQ 100.9 ± 15.8 107.8 ± 13.4 101.2 ± 16.5 105.7 ± 12.7 F(3,171) = 1.67; p 
= 0.18
Medications (#/% yes)
    Anti-psychotic 53 (65.4 %) 4 (36.4 %) 17 (60.7 %) X2 = 3.48, p = 
0.18
    Anti-depressant 14 (17.3 %) 4 (36.4 %) 5 (17.9 %) X2 = 2.32; p = 
0.31
    Stimulant 34 (42.0 %) 2 (18.2 %) 6 (21.4 %) X2 = 5.37; p = 
0.07
    Anti-epileptic drug 26 (32.1 %) 3 (27.3 %) 6 (21.4 %) X2 = 1.17; p = 
0.56
    Benzodiazepine 2 (2.4 %) 1 (9.1 %) 2 (7.1 %) X2 = 1.87; p=0.39
    Lithium 21 (25.9 %) 0 (0%) 3 (10.7 %) X2 = 6.04; p = 
0.05
Mood state
    Depression past 2 days (KSADS–DSR) X2 = 3.44; p = 
0.49
        Not (DSR<10) 66 (81.5 %) 7 (63.6 %) 24 (85.7 %)
        Some (DSR 10–19) 13 (16.0 %) 4 (36.4 %) 4 (14.3 %)
        Substantial (DSR >20) 1 (1.2 %) 0 (0 %) 0 (0 %)
    Mania past 2 days (KSADS–MRS) X2 = 2.68; p = 
0.61
        Not (MRS<10) 60 (74.1 %) 8 (72.7 %) 24 (85.7 %)
        Some (MRS 10–19) 14 (17.3 %) 2 (18.2 %) 4 (14.3 %)
        Substantial (MRS>20) 6 (7.4 %) 1 (9.1 %) 0 (0 %)
    Mood episode status past week X2 = 18.16; p = 
0.006
        Euthymic 28 (34.6 %) 6 (54.5 %) 14 (50 %)
        Sub-threshold 41 (50.6 %) 1 (9. 1 %) 13 (16.0 %)
        Full threshold MDE 3 (3.7 %) 3 (27.3 %) 1 (3.6 %)
        Full threshold hypo/mania/mixed/hypomixed 9 (11.1 %) 1 (9. 1 %) 0 (0 %)
BD bipolar disorder, NOS not otherwise specified, TDC typically developing controls, KSADS schedule for affective disorders and schizophrenia 
for school-age children, DRS Depression Rating Scale, MRS Mania Rating Scale, MDE major depressive episode
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Table 2
CANTAB performance grouped by BD-I /II vs. BD-NOS vs. TDC
BD-I/II (N = 92) BD-NOS (N = 28) TDCa Wilks’ Lambda
Intra-dimensional/extra-dimensional shift (IDED) task F(12,334) = 1.72 p = 0.06
    Stages completed 8.24 ± 1.24 7.86 ± 0.97 8.45 ± 0.86
    Total errors 23.77 ± 12.18 27.04 ± 12.03 20.69 ± 11.72
    Completed stage trials 74.23 ± 20.28 64.68 ± 15.47 70.78 ± 16.76
    Total trials 92.16 ± 19.58 95.04 ± 17.85 86.24 ± 19.30
    Pre-ED errors 8.28 ± 5.42 7.36 ± 3.66 6.60 ± 3.18
    ED shift errors 12.63 ± 10.53 17.25 ± 11.49 10.87 ± 10.09
Pattern recognition memory (PRM) F(4,278) = 2.04 p = 0.09
    Number correct 21.28 ± 2.29 20.36 ± 3.65 22.00 ± 2.13
    Mean correct latency 2249.93 ± 569.19 2386.26 ± 720.49 2018.16 ± 422.49
Rapid visual processing (RVP) F(12,272) = 17.60 p < 0.001
    RVP A′ 0.84 ± 0.08 0.84 ± 0.06 0.97 ± 0.03
    RVP B″ 0.70 ± 0.40 0.60 ± 0.48 0.63 ± 0.59
Total correct rejections 229.53 ± 28.15 222.93 ± 30.38 264.89 ± 9.93
Total false alarms 14.30 ± 28.65 21.70 ± 33.80 4.18 ± 6.42
Probability of hit 0.51 ± 0.22 0.53 ± 0.22 0.87 ± 0.11
Probability of false alarm 0.06 ± 0.11 0.09 ± 0.13 0.02 ± 0.03
Spatial span (SSP) F(6,276) = 2.02 p = 0.06
Span length 5.84 ± 1.39 5.75 ± 1.62 6.61 ± 1.44
Total errors 14.60 ± 6.88 12.14 ± 5.73 13.74 ± 6.77
Total usage errors 2.64 ± 1.95 2.75 ± 1.78 1.83 ± 1.75
Affective Go/No Go F(6,338) = 2.19 p = 0.04
Mean correct latency 446.79 ± 88.39 435.47 ± 100.21 460.23 ± 108.30
Total commissions 29.48 ± 15.44 35.64 ± 16.32 36.04 ± 34.04
Total omissions 20.28 ± 14.22 16.89 ± 13.23 24.15 ± 20.65
Rightmost two columns indicate results of multivariate statistical analyses for each CANTAB test
BD bipolar disorder, NOS not otherwise specified, TDC typically developing controls, ID/ED inter-dimensional/extra-dimensional shift task, PRN 
pattern recognition memory, RVP rapid visual processing, SSP spatial span, AGN Affective Go/No Go
a
LAMS TDC participants (N = 32) completed IDED, RVP, AGN. PediMIND TDC participants (N = 23) completed IDED, PRM, SSP, AGN
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Table 3
CANTAB performance by group
BD-I (N = 81) BD-II (N = 11) BD-NOS (N = 
28) TDC
a Wilks’ Lambda
IDED F(18,470) = 1.34 p = 0.16
    Stages completed 8.19 ± 1.29 8.64 ± 0.81 7.86 ± 0.97 8.45 ± 0.86
    Total errors 24.49 ± 12.41 18.45 ± 9.07 27.04 ± 12.03 20.69 ± 11.72
    Completed stage trials 74.06 ± 21.01 75.45 ± 14.48 64.68 ± 15.47 70.78 ± 16.76
    Total trials 93.20 ± 20.21 84.55 ± 12.23 95.04 ± 17.86 86.24 ± 19.30
    Pre-ED errors 8.33 ± 5.72 7.91 ± 2.21 7.36 ± 3.66 6.60 ± 3.18
    ED shift errors 13.05 ± 10.61 9.55 ± 9.81 17.25 ± 11.49 10.87 ± 10.09
Pattern recognition memory F(6,276) = 1.37 p = 0.23
    Number correct 21.27 ± 2.30 21.36 ± 2.34 20.36 ± 3.65 22.00 ± 2.13
    Mean correct latency 2244.63 ± 583.49 2288.92 ± 471.84 2386.26 ± 720.49 2018.16 ± 422.49
Rapid visual processing F(18,382) = 10.78 p < 0.001
    RVP A′ 0.84 ± 0.09 0.85 ± 0.07 0.84 ± 0.06 0.97 ± 0.03
    RVP B″ 0.70 ± 0.40 0.66 ± 0.42 0.60 ± 0.48 0.63 ± 0.59
    Total correct rejections 229.92 ± 27.32 226.73 ± 34.88 222.93 ± 30.38 264.89 ± 9.93
    Total false alarms 13.71 ± 27.90 18.55 ± 34.71 21.70 ± 33.80 4.18 ± 6.42
    Probability of hit 0.51 ± 0.22 0.55 ± 0.24 0.53 ± 0.22 0.87 ± 0.11
    Probability of false alarm 0.06 ± 0.11 0.07 ± 0.14 0.09 ± 0.13 0.02 ± 0.03
Spatial span (SSP) F(9,333) = 1.79 p = 0.07
    Span length 5.74 ± 1.39 6.55 ± 1.29 5.75 ± 1.62 6.61 ± 1.44
    Total errors 14.23 ± 6.71 17.27 ± 7.84 12.14 ± 5.73 13.74 ± 6.77
    Total usage errors 2.68 ± 1.99 2.36 ± 1.69 2.75 ± 1.77 1.83 ± 1.75
Affective Go/No Go F(9,409) = 2.98 p = 0.15
    Mean correct latency 446.21 ± 87.41 451.04 ± 99.71 435.47 ± 100.21 460.23 ± 108.30
    Total commissions 29.99 ± 15.48 25.73 ± 15.31 35.64 ± 16.32 36.04 ± 34.05
    Total omissions 20.51 ± 14.04 18.64 ± 16.12 16.89 ± 13.23 24.15 ± 20.65
Rightmost two columns indicate results of multivariate statistical analyses for each CANTAB test
BD bipolar disorder, NOS not otherwise specified, TDC typically developing controls, ID/ED inter-dimensional/extra-dimensional shift task, PRN 
pattern recognition memory, RVP rapid visual processing, SSP spatial span, AGN Affective Go/No Go
a
LAMS TDC participants (N = 32) completed IDED, RVP, AGN. PediMIND TDC participants (N = 23) completed IDED, PRM, SSP, AGN
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